Skip to content

US · VERA · BIOTECHNOLOGY

Vera Therapeutics, Inc. (VERA) intrinsic value and stock valuation

$25.45as of 2026-11-21 · Mkt cap 2.18B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vera Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VERA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VERA’s statements →

Vera Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Brisbane, CA 94005 veratx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-299.62M
20192025
Free cash flow
-$-241.73M
20192025
Total equity
$604.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-315.47M-$-167.17M-$-102.01M-$-90.9M-$-34.4M
Net income-$-299.62M-$-152.15M-$-95.99M-$-89.06M-$-32.61M
EPSd-$-4.66M-$-2.75M-$-2.25M-$-3.35M-$-2.43M
Operating cash flow-$-241.1M-$-134.68M-$-92.18M-$-67.6M-$-23.71M
Capital expenditure-$-630K-$-970K-$-60K-$-60K$0.00
Free cash flow-$-241.73M-$-135.65M-$-92.24M-$-67.66M-$-23.71M
Total assets$734.7M$655.7M$175.6M$131.4M$83.8M
Total debt$77.3M$54.6M$53.7M$31.3M$4.92M
Net debt-$-277.42M-$-38.01M$8.03M-$-12.17M-$-74.75M
Total equity$604.5M$577.2M$101.7M$76.9M$69.6M
Cash and short-term investments$714.6M$640.9M$160.7M$114.7M$79.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00-$-850K$0.00
Gross profit$0.00$0.00$0.00$850K$0.00
Research and development expenses$215.3M$126.2M$78.2M$69.8M$22.5M
Selling, general and administrative expenses$100.2M$41M$23.8M$21.9M$11.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$315.5M$167.2M$102M$91.8M$34.4M
Cost and expenses$315.5M$167.2M$102M$90.9M$34.4M
Interest income$24.5M$20.7M$7.98M$1.75M$10K
Interest expense$7.53M$7.63M$3.79M$990K$20K
Depreciation and amortization$470K$100K$20K-$-850K$180K
Ebitda-$-291.62M-$-144.42M-$-92.18M-$-88.91M-$-32.41M
Operating income-$-315.47M-$-167.17M-$-102.01M-$-90.9M-$-34.4M
Total other income/expenses, net$15.9M$15M$6.02M$1.85M$1.79M
Income before tax-$-299.61M-$-152.15M-$-95.99M-$-89.06M-$-32.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-299.62M-$-152.15M-$-95.99M-$-89.06M-$-32.61M
Weighted average shares outstanding$64.2M$55.3M$42.7M$26.6M$13.4M
Weighted average diluted shares outstanding$64.2M$55.3M$42.7M$26.6M$13.4M
Balance sheet
20252024202320222021
Cash and short-term investments$714.6M$640.9M$160.7M$114.7M$79.7M
Net receivables$3.29M$3.77M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$728.9M$651.2M$172M$125.7M$82.5M
Property, plant and equipment, net$1.92M$4.33M$3.04M$5.22M$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$10K$60K$870K
Total non-current assets$5.85M$4.46M$3.52M$5.74M$1.21M
Total assets$734.7M$655.7M$175.6M$131.4M$83.8M
Accounts payable$21.9M$7.67M$11.1M$12M$1.39M
Short-term debt$550K$1.48M$2.44M$2.65M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$53.5M$25.4M$22.3M$25.6M$7.69M
Long-term debt$76.8M$53.2M$51.3M$28.6M$4.92M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$76.8M$53.2M$51.6M$28.9M$6.47M
Capital lease obligations$2.47M$3.95M$3.83M$6.48M$0.00
Total liabilities$130.2M$78.5M$73.9M$54.5M$14.2M
Common stock$70K$60K$40K$30K$20K
Retained earnings-$-760.87M-$-461.25M-$-309.1M-$-213.11M-$-124.06M
Accumulated other comprehensive income (loss)$790K$390K$250K-$-220K-$0.00
Total equity$604.5M$577.2M$101.7M$76.9M$69.6M
Total investments$359.9M$548.2M$115.1M$71.3M$870K
Total debt$77.3M$54.6M$53.7M$31.3M$4.92M
Net debt-$-277.42M-$-38.01M$8.03M-$-12.17M-$-74.75M
Cash flow statement
20252024202320222021
Net income-$-299.62M-$-152.15M-$-95.99M-$-89.06M-$-32.61M
Depreciation and amortization$470K$100K-$-4.09M-$-850K$180K
Stock-based compensation$37.9M$20.8M$11.5M$8.89M$3.01M
Change in working capital$23M$2.66M-$-5.87M$6.75M$3.51M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$13.9M-$-3.45M-$-870K$10.6M$470K
Net cash provided by operating activities-$-241.1M-$-134.68M-$-92.18M-$-67.6M-$-23.71M
Investments in property, plant and equipment-$-630K-$-970K-$-60K-$-60K$0.00
Acquisitions, net$0.00$0.00$0.00$70K$800K
Net cash used for investing activities$194.3M-$-425.03M-$-39.43M-$-70.55M-$-4.2M
Common stock issued$307.5M$632.5M$115M$86.1M$51.2M
Common stock repurchased$0.00-$-10K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$308.9M$606.7M$133.5M$101.9M$53.9M
Net change in cash$262.1M$47M$1.93M-$-36.22M$26M
Cash at end of period$354.7M$92.7M$45.7M$43.8M$80M
Operating cash flow-$-241.1M-$-134.68M-$-92.18M-$-67.6M-$-23.71M
Capital expenditure-$-630K-$-970K-$-60K-$-60K$0.00
Free cash flow-$-241.73M-$-135.65M-$-92.24M-$-67.66M-$-23.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vera Therapeutics, Inc.

        Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

        CEO
        Marshall Fordyce
        Employees
        249
        Beta
        0.92

        Explore

        Frequently asked questions

        What is the intrinsic value of Vera Therapeutics, Inc. (VERA)?

        InvestorsCraft does not currently publish an intrinsic value for VERA. How the IC value is calculated.

        Is VERA undervalued?

        InvestorsCraft does not publish an undervaluation signal for VERA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.